Seattle Cannabis Company Capitalizes on Surging Demand
The increase in the number of states that permit recreational and medical use of cannabis means that growers, processors and manufacturers of cannabis products often can’t keep up with growing demand. One Seattle weed manufacturer is poised to sell products across state lines, easing shortages. This could drive the company’s shares sky-high.
Get all the details on this potential blockbuster!

ANGN Insider Trading (Angion Biomedica)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,548,640.15

Angion Biomedica Insider Trading History Chart

This chart shows the insider buying and selling history at Angion Biomedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Angion Biomedica Share Price & Price History

Current Price: $13.45
Price Change: Price Increase of +0.17 (1.28%)
As of 06/24/2021 11:46 AM ET

This chart shows the closing price history over time for ANGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The EU Lithium Battery Boom
This Company Made a Lithium Discovery That Could Solve Europe's Lithium Shortage!

That's great news for investors. Discover why HERE.
Get Your Battery Boom Report Now!

Angion Biomedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/18/2021John F NeylanInsiderSell366$13.20$4,831.2037,363View SEC Filing Icon  
6/14/2021Jennifer J RhodesInsiderSell427$13.27$5,666.2933,020View SEC Filing Icon  
5/18/2021John F NeylanInsiderSell363$13.91$5,049.3337,729View SEC Filing Icon  
4/19/2021John F NeylanInsiderSell381$13.55$5,162.5538,092View SEC Filing Icon  
4/15/2021Jennifer J RhodesInsiderSell399$15.01$5,988.9933,887View SEC Filing Icon  
3/17/2021John F NeylanInsiderSell442$19.13$8,455.4638,453View SEC Filing Icon  
3/13/2021Jennifer J RhodesInsiderSell499$20.45$10,204.5534,286View SEC Filing Icon  
2/13/2021Jennifer J RhodesInsiderSell457$19.54$8,929.7834,785View SEC Filing Icon  
2/9/2021Jay VenkatesanInsiderSell159,177$16.00$2,546,832.00View SEC Filing Icon  
2/9/2021Victor F GanziDirectorSell246,720$16.00$3,947,520.00405,405View SEC Filing Icon  
See Full Table
Insider Buying at Angion Biomedica?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Angion Biomedica and related companies.

SEC Filings (Institutional Ownership Changes) for Angion Biomedica (NASDAQ:ANGN)

17.03% of Angion Biomedica stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ANGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Angion Biomedica Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
6/14/2021Knoll Capital Management LLC60,000$1.08M0.7%N/A0.202%Search for SEC Filing on Google Icon
5/18/2021BVF Inc. IL875,000$15.81M0.6%N/A2.968%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC33,260$0.60M0.0%N/A0.113%Search for SEC Filing on Google Icon
5/18/2021Zimmer Partners LP21,875$0.40M0.0%N/A0.074%Search for SEC Filing on Google Icon
5/18/2021Alyeska Investment Group L.P.50,000$0.90M0.0%N/A0.170%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC34,956$0.63M0.0%N/A0.118%Search for SEC Filing on Google Icon
5/18/2021Park West Asset Management LLC966,654$17M0.5%N/A3.279%Search for SEC Filing on Google Icon
5/18/2021California State Teachers Retirement System8,756$0.16M0.0%N/A0.030%Search for SEC Filing on Google Icon
5/14/2021Nantahala Capital Management LLC125,000$2.26M0.1%N/A0.424%Search for SEC Filing on Google Icon
5/14/2021Birchview Capital LP60,615$1.10M0.7%N/A0.206%Search for SEC Filing on Google Icon
5/13/2021Franklin Resources Inc.615,000$11.11M0.0%N/A2.086%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp10,417$0.19M0.0%N/A0.035%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp64,724$1.17M0.0%N/A0.220%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC95,306$1.72M0.0%N/A0.323%Search for SEC Filing on Google Icon
5/12/2021CM Management LLC93,750$1.69M1.3%N/A0.318%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.179,488$3.24M0.0%N/A0.609%Search for SEC Filing on Google Icon
5/12/2021UBS Group AG1,630$29K0.0%N/A0.006%Search for SEC Filing on Google Icon
5/11/2021New York State Common Retirement Fund2,900$52K0.0%N/A0.010%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.313,713$5.67M0.0%N/A1.064%Search for SEC Filing on Google Icon
5/7/2021American International Group Inc.3,384$61K0.0%N/A0.011%Search for SEC Filing on Google Icon
5/4/2021Victory Capital Management Inc.82,620$1.49M0.0%N/A0.280%Search for SEC Filing on Google Icon
4/29/2021CAPROCK Group Inc.15,726$0.28M0.0%N/A0.053%Search for SEC Filing on Google Icon
4/23/2021Strs Ohio1,400$25K0.0%N/A0.005%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.
Read More on Angion Biomedica

Today's Range

Now: $13.45
Low: $13.36
High: $13.49

50 Day Range

MA: $14.20
Low: $13.02
High: $16.06

52 Week Range

Now: $13.45
Low: $12.45
High: $26.30

Volume

329 shs

Average Volume

124,035 shs

Market Capitalization

$398.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Angion Biomedica?

Angion Biomedica's top insider shareholders include:
  1. Victor F Ganzi (Director)
  2. John F Neylan (Insider)
  3. Jennifer J Rhodes (Insider)
  4. Jay Venkatesan (Insider)

Who are the major institutional investors of Angion Biomedica?

Angion Biomedica's top institutional investors include:
  1. Park West Asset Management LLC — 3.28%
  2. BVF Inc. IL — 2.97%
  3. Franklin Resources Inc. — 2.09%
  4. BlackRock Inc. — 1.06%
  5. JPMorgan Chase & Co. — 0.61%
  6. Nantahala Capital Management LLC — 0.42%

Which institutional investors are buying Angion Biomedica stock?

Within the previous quarter, ANGN stock was acquired by institutional investors including:
  1. Park West Asset Management LLC
  2. BVF Inc. IL
  3. Franklin Resources Inc.
  4. BlackRock Inc.
  5. JPMorgan Chase & Co.
  6. Nantahala Capital Management LLC
  7. Geode Capital Management LLC
  8. CM Management LLC
Why Are Billionaire Investors Betting On The 2021 Mental Health Revolution?
Investors say this little-known sector feels exactly like CBD did in 2017. This new technology is making investors like Peter Thiel very excited.
See How Early "Mental Health Revolution" Investors